Inhibition Of IFN-?/? By Human Metapneumovirus And The Induction Of Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$605,251.00
Summary
The newly isolated human metapneumovirus (hMPV) causes significant respiratory illness in infants, young children and the elderly. The virus can persist long-term and may predispose individuals to chronic lung disease. This proposal aims to determine the mechanisms by which hMPV infection causes respiratory disease, with a view to improving treatments and preventing disease.
Circulatory Biomarkers For Idiopathic Pulmonary Fibrosis: Improving Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$841,625.00
Summary
We are going to find molecules in the blood that would improve the diagnosis and treatment of a lung condition called Idiopathic Pulmonary Fibrosis (IPF). The project brings together well characterized patients from the Australian IPF registry, blood samples we have collected from them and cutting edge technologies to complete this project.
A Randomised Controlled Trial Of Interventional Versus Conservative Treatment Of Primary Spontaneous Pneumothorax
Funder
National Health and Medical Research Council
Funding Amount
$412,315.00
Summary
Primary spontaneous pneumothorax (PSP) is a collapsed lung that occurs in otherwise healthy people without underlying lung disease. Current standard treatment is to insert a chest drain into the chest to remove the air around the collapsed lung so that the lung re-inflates rapidly ("interventional treatment"). We will determine whether doing nothing, i.e. letting the lung re-inflate slowly on its own over several weeks ("conservative treatment"), is just as good or even better for patients.
How Neural Impairment Affects Respiratory Motor Function In Chronic Obstructive Pulmonary Disease And Healthy Ageing
Funder
National Health and Medical Research Council
Funding Amount
$762,797.00
Summary
With chronic obstructive pulmonary disease (COPD) and ageing, respiratory muscles are weak and the mechanics of the chest and lungs are altered. Our proposal will examine the contribution of impaired neural control to muscle weakness with the aim to identify new targets for therapy to reduce respiratory morbidity in ageing and patients with COPD.
Extending The MIS BAIR Randomised Trial Of BCG To Prevent Childhood Allergy And Infection
Funder
National Health and Medical Research Council
Funding Amount
$939,504.00
Summary
BCG (used till recently to prevent tuberculosis) is a potential low cost and readily available vaccine which could reduce the rates of allergy and infection in Australian children. We propose to extend our existing NHMRC-funded trial, which studies whether BCG vaccinatinon given at birth prevents the development food allergy, eczema and infection in the 1st year of life, to see if this effect continues until 5yrs of age. At this age, we can also see if BCG vaccination at birth prevents asthma.
Active Lung Disease In Survivors Of Preterm Birth? Can We Treat It?
Funder
National Health and Medical Research Council
Funding Amount
$612,862.00
Summary
More than 15 million babies are born preterm each year. Those that survive face a lifetime of ongoing breathing problems and lung function that worsens through childhood. Our study will work out how inflammation in the lungs contributes to these ongoing breathing problems during childhood. We will also look at how the exhaled breath of preterm children is different to term children and test how treatment with an inhaled anti-inflammatory medicine changes the lung disease in preterm children.
Prediction Of Clinical Outcomes In COPD From Home Monitoring Of Lung Function Variability
Funder
National Health and Medical Research Council
Funding Amount
$513,102.00
Summary
Chronic obstructive pulmonary disease affects close to 30% of the elderly and is the fourth leading cause of male deaths in Australia. There are currently no objective ways to assess disease status and predict future risk of deterioration. We aim to apply novel, sophisticated analysis methods to data from daily home telemonitoring, in order to describe the variability of disease over time and predict risk of exacerbations and quality of life.
Personalised Medicine For Mitochondrial Disorders: Targeting Pathogenic Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$1,770,213.00
Summary
Mitochondria are our cellular power plants that burn sugars, fats and proteins to generate energy. Each week in Australia a child is born with a mitochondrial disorder. Many of these children die in the first years of life and most suffer from severe disease, particularly affecting their brain and/or heart. We will use stem cell models to better understand the basic biology of these disorders and to develop targeted therapies to improve the outcomes for affected patients.
The Role Of Accessory Subunits And Assembly Factors In The Biogenesis Of Respiratory Chain Complex I
Funder
National Health and Medical Research Council
Funding Amount
$569,987.00
Summary
The mitochondrial respiratory chain produces most of the energy required for our cells to grow and function. Complex I is the first enzyme of this chain and its defects are the most prevalent cause of mitochondrial disease, which often results in infant fatality. Defects in complex I have also been associated with Parkinson's disease and oxidative stress. This study will provide important new information into how complex I is built and what goes wrong to cause disease.
Understanding The Interplay Between ER Stress And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$560,918.00
Summary
Chronic inflammatory diseases in the gut and lung affect hundreds of thousands of Australians. We have identified how inflammation causes a type of stress resulting in abnormal protein synthesis in the cells which make the barrier to microbes. Following an infection this process might be the trigger for chronic unresolving inflammatory disease. The further understanding of this process we seek in this project is likely to lead new approaches to treat common inflammatory diseases.